Towerview LLC Acquires 42,500 Shares of Corvus Pharmaceuticals, Inc. $CRVS

Towerview LLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 33.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 170,000 shares of the company’s stock after buying an additional 42,500 shares during the period. Corvus Pharmaceuticals comprises 0.5% of Towerview LLC’s portfolio, making the stock its 15th largest holding. Towerview LLC owned 0.25% of Corvus Pharmaceuticals worth $680,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of CRVS. Jump Financial LLC purchased a new stake in shares of Corvus Pharmaceuticals in the 1st quarter worth $143,000. Masso Torrence Wealth Management Inc. lifted its position in shares of Corvus Pharmaceuticals by 42.9% during the 2nd quarter. Masso Torrence Wealth Management Inc. now owns 50,000 shares of the company’s stock valued at $200,000 after buying an additional 15,000 shares in the last quarter. OMERS ADMINISTRATION Corp grew its stake in shares of Corvus Pharmaceuticals by 9.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 82,300 shares of the company’s stock valued at $262,000 after acquiring an additional 6,800 shares during the period. American Century Companies Inc. increased its holdings in Corvus Pharmaceuticals by 103.9% in the 1st quarter. American Century Companies Inc. now owns 89,265 shares of the company’s stock worth $284,000 after acquiring an additional 45,491 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in Corvus Pharmaceuticals during the 1st quarter valued at approximately $333,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

CRVS opened at $7.82 on Friday. The company has a market capitalization of $584.00 million, a P/E ratio of -14.75 and a beta of 0.56. Corvus Pharmaceuticals, Inc. has a 1-year low of $2.54 and a 1-year high of $10.00. The company has a 50-day moving average of $6.81 and a 200-day moving average of $5.07.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. As a group, sell-side analysts expect that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on CRVS. Wall Street Zen lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, October 18th. Barclays assumed coverage on shares of Corvus Pharmaceuticals in a report on Monday, October 13th. They issued an “overweight” rating and a $16.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Mizuho set a $13.00 price target on Corvus Pharmaceuticals in a report on Wednesday, October 29th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.